Abstract:BackgroundIschemic heart diseases are still a threat to human health. Human pluripotent stem cell-based transplantation exhibits great promise in cardiovascular disease therapy, including heart ischemia. The purpose of this study was to compare the efficacy of human embryonic stem cell-derived cardiomyocyte (ESC-CM) therapy in two heart ischemia models, namely, permanent ischemia (PI) and myocardial ischemia reperfusion (IR).MethodsHuman embryonic stem cell-derived cardiomyocytes were differentiated from engineered human embryonic stem cells (ESC-Rep) carrying green fluorescent protein (GFP), herpes simplex virus-1 thymidine kinase (HSVtk), and firefly luciferase (Fluc). Two different heart ischemia models were generated by the ligation of the left anterior descending artery (LAD), and ESC-Rep-derived cardiomyocytes (ESC-Rep-CMs) were transplanted into the mouse hearts. Cardiac function was analyzed to evaluate the outcomes of ESC-Rep-CM transplantation. Bioluminescence signal analysis was performed to assess the cell engraftment. Finally, the inflammation response was analyzed by real-time PCR and ELISA.ResultsCardiac function was significantly improved in the PI group with ESC-Rep-CM injection compared to the PBS-injected control, as indicated by increased left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), as well as reduced fibrotic area. However, minimal improvement by ESC-Rep-CM injection was detected in the IR mouse model. We observed similar engraftment efficiency between PI and IR groups after ESC-Rep-CM injection. However, the restricted inflammation was observed after the injection of ESC-Rep-CMs in the PI group, but not in the IR group. Transplantation of ESC-Rep-CMs can partially preserve the heart function via regulating the inflammation response in the PI model, while little improvement of cardiac function in the IR model may be due to the less dynamic inflammation response by the mild heart damage.ConclusionsOur findings identified the anti-inflammatory effect of ESC-CMs as a possible therapeutic mechanism to improve cardiac function in the ischemic heart.

Puerarin Facilitates T-tubule Development of Murine Embryonic Stem Cell-Derived Cardiomyocytes.

Puerarin Enhances Ca2+ Reuptake and Ca2+ Content of Sarcoplasmic Reticulum in Murine Embryonic Stem Cell-Derived Cardiomyocytes Via Upregulation of SERCA2a

Effects of puerarin on cardiac differentiation and ventricular specialization of murine embryonic stem cells.

Time-dependence of Cardiomyocyte Differentiation Disturbed by Peroxisome Proliferator-Activated Receptor Α Inhibitor GW6471 in Murine Embryonic Stem Cells in Vitro

Icariin Promotes Expression of Junctophilin 2 and Ca2+ Related Function During Cardiomyocyte Differentiation of Murine Embryonic Stem Cells.

Puerarin Reduces Endothelial Progenitor Cells Senescence Through Augmentation of Telomerase Activity

PGC-1α Activator ZLN005 Promotes Maturation of Cardiomyocytes Derived from Human Embryonic Stem Cells.

Direct Differentiation of Atrial and Ventricular Myocytes from Human Embryonic Stem Cells by Alternating Retinoid Signals

Puerarin Exerts a Delayed Inhibitory Effect on the Proliferation of Cardiomyocytes Derived from Murine ES Cells Via Slowing Progression Through G2/M Phase.

Icariin Promotes Expression of PGC-1α, PPARα, and NRF-1 During Cardiomyocyte Differentiation of Murine Embryonic Stem Cells in Vitro

MiR‐218 Regulated Cardiomyocyte Differentiation and Migration in Mouse Embryonic Stem Cells by Targeting PDGFRα

Peroxisome proliferator-activated receptor alpha is involved in cardiomyocyte differentiation of murine embryonic stem cells in vitro.

Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro.

Puerarin Suppresses the Self-Renewal of Murine Embryonic Stem Cells by Inhibition of REST-MiR-21 Regulatory Pathway

Icariin-mediated Expression of Cardiac Genes and Modulation of Nitric Oxide Signaling Pathway During Differentiation of Mouse Embryonic Stem Cells into Cardiomyocytes in Vitro.

Puerarin Protects Against Cardiac Fibrosis Associated with the Inhibition of TGF-β1/Smad2-Mediated Endothelial-to-Mesenchymal Transition.

Efficient Cardiomyocyte Differentiation of Embryonic Stem Cells by Bone Morphogenetic Protein-2 Combined with Visceral Endoderm-Like Cells.

MiR-301a Promotes Embryonic Stem Cell Differentiation to Cardiomyocytes.

Pericardial Delivery of SDF-1 Α Puerarin Hydrogel Promotes Heart Repair and Electrical Coupling

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy in Mouse Permanent Ischemia and Ischemia-Reperfusion Models

Baicalin Maintains Late-Stage Functional Cardiomyocytes in Embryoid Bodies Derived from Murine Embryonic Stem Cells